The molecular biology of lung cancer brain metastasis: an overview of current comprehensions and future perspectives

J Med Invest. 2014;61(3-4):241-53. doi: 10.2152/jmi.61.241.

Abstract

Brain metastases occur in 20-40% of patients with advanced malignancies and lung cancer is one of the most common causes of brain metastases. The occurrence of brain metastases is associated with poor prognosis and high morbidity in patients with advanced lung cancer, even after intensive multimodal therapy. Progress in treating brain metastases has been hampered by a lack of model systems, a lack of human tissue samples, and the exclusion of brain metastatic patients from many clinical trials. While the biology of brain metastasis is still poorly understood, it is encouraging to see more efforts are beginning to be directed toward the study of brain metastasis. During the multi-step process of metastasis, functional significance of gene expressions, changes in brain vasculature, abnormal secretion of soluble factors and activation of autocrine/paracrine signaling are considered to contribute to the brain metastasis development. A better understanding of the mechanism of this disease will help us to identify the appropriate therapeutic strategies, which leads to circumvent brain metastases. Recent findings on the biology of lung cancer brain metastases and translational leads identified by molecular studies are discussed in this review.

Publication types

  • Review

MeSH terms

  • Astrocytes / physiology
  • Brain Neoplasms / secondary*
  • Brain Neoplasms / therapy
  • Cadherins / physiology
  • ErbB Receptors / genetics
  • Humans
  • Integrins / physiology
  • Lung Neoplasms / pathology*
  • Molecular Targeted Therapy
  • Polymorphism, Single Nucleotide
  • Vascular Endothelial Growth Factor A / physiology

Substances

  • Cadherins
  • Integrins
  • Vascular Endothelial Growth Factor A
  • ErbB Receptors